Agonist and Inverse Agonist Actions of β-Blockers at the Human β2-Adrenoceptor Provide Evidence for Agonist-Directed Signaling

Molecular Pharmacology

Volumn 64, Issue 6, 2003, Pages 1357-1369

  Baker, Jillian G ^a   Hall, Ian P ^a   Hill, Stephen J ^a,b  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b QUEEN S MEDICAL CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3 ISOPROPYLAMINO 1 (7 METHYL 4 INDANYLOXY) 2 BUTANOL; 5 [2 [[2 HYDROXY 3 [4 (1 METHYL 4 TRIFLUOROMETHYL 2 IMIDAZOLYL)PHENOXY]PROPYL]AMINO]ETHOXY]SALICYLAMIDE; ACEBUTOLOL; ADENYLATE CYCLASE; ALPRENOLOL; ATENOLOL; BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BUPRANOLOL; CARVEDILOL; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP DERIVATIVE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; FORSKOLIN; GUANINE NUCLEOTIDE BINDING PROTEIN; INOSITOL PHOSPHATE; LABETALOL; METOPROLOL; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; PERTUSSIS TOXIN; PINDOLOL; PROPRANOLOL; PROTEIN KINASE C INHIBITOR; RHO KINASE; SOTALOL; TIMOLOL;

ANIMAL CELL; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYCLIC AMP RESPONSIVE ELEMENT; DRUG MECHANISM; DRUG RECEPTOR BINDING; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC TRANSCRIPTION; HEART FAILURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ADRENERGIC BETA-AGONISTS; ADRENERGIC BETA-ANTAGONISTS; ANIMALS; CHO CELLS; CRICETINAE; CYCLIC AMP; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; HUMANS; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASES; RECEPTORS, ADRENERGIC, BETA-2;

EID: 0345735773     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.64.6.1357     Document Type: Article

References (40)

1. Alessi DR (1997) The protein kinase C inhibitors RO 318220 and GF 109203X are equally potent inhibitors of MAPKAP kinase-1β (Rsk-2) and p70 S6 kinase. FEBS Lett 402:121-123.
2. Azzi M, Pineyro G, Pontier S, Parent S, Ansanay H, and Bouvier M (2001) Allosteric effects of G protein overexpression on the binding of β-adrenergic ligands with distinct inverse efficacies. Mol Pharmacol 60:999-1007.
3. 2-adrenoceptor. Br J Pharmacol 137:400-408.
4. Baker JG, Hall IP, and Hill SJ (2003) Agonist actions of "β-blockers" provide evidence for two agonist activation sites on the human β1-adrenoceptor. Mol Pharmacol 63:1312-1321.
5. BEST (Beta-blocker Evaluation of Survival Trial Investigators) (2001) A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 344:1659-1667.
6. 2-adrenoceptor. Nature (Lond) 374:272-276.
7. Bond RA (2001) Is paradoxical pharmacology a strategy worth pursuing? Trends Pharmacol Sci 22:273-276.
8. Brzostowski JA and Kimmel AR (2001) Signaling at zero G: G-protein-independent functions for 7-TM receptors. Trends Biochem Sci 26:291-297.
9. CIBIS-II (1999) The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 353:9-13, 1999.
10. Chidiac P, Hebert TE, Valiquette M, Dennis M, and Bouvier M (1994) Inverse agonist activity of β-adrenergic antagonists. Mol Pharmacol 45:490-499.
11. Daaka Y, Luttrell LM, Ahn S, Della Rocca GJ, Fergusson SSG, Caron MG, and Lefkowitz RJ (1998) Essential role for G protein-coupled receptor endocytosis on the activation of mitogen-activated protein kinase. J Biol Chem 273:685-688.
12. Daaka Y, Luttrell LM, and Lefkowitz RJ (1997) Switching of the coupling of the beta 2-adrenergic receptor to different G-proteins by protein kinase A. Nature (Lond) 390:88-91.
13. Davies SP, Reddy H, Caivano M, and Chen P (2000) Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 351:95-105.
14. de Rooij J, Rehmann H, van Triest M, Cool RH, Wittinghofer A, and Bos JL (2000) Mechanism of regulation of the Epac family of cAMP-dependent RapGEFs. J Biol Chem 275:20829-20836.
15. Eichhorn EJ and Bristow MR (2001) The carvedilol prospective randomised cumulative survival (COPERNICUS) trial. Curr Control Trials Cardiovasc Med 2:20-23.
16. English JM and Cobb MH (2002) Pharmacological inhibitors of MAPK pathways. Trends Pharmacol Sci 23:40-45.
17. 2-adrenergic receptor via phospho-tyr-350, phosphorylates G-protein-linked receptor kinase 2 and mediates agonist-induced receptor desensitization. J Biol Chem 276:13240-13247.
18. Favata MF, Horiuchi KY, Manos EJ, Daulerio AJ, Stradley DA, Feeser WS, Van Dyk DE, Pitts WJ, Earl RA, Hobbs F, et al (1998) Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem 273:18623-18632.
19. i switching. Mol Pharmacol 62:1094-1102.
20. 13 in receptor-mediated stress fiber formation. J Biol Chem 274:17901-17907.
21. + exchange. Nature (Lond), 392:626-630.
22. Heidenreich PA, McDonald KM, Hastie T, Fadel B, Hagan V, Lee BK, and Hlatky MA (1999) Meta-analysis of trials comparing beta-blockers, calcium antagonists and nitrates for stable angina. J Am Med Assoc 281:1927-1936.
23. Howe R and Shanks RG (1966) Optical isomers of propranolol. Nature (Lond) 210:1336-1338.
24. Jasper JR, Michel MC, and Insel PA (1990) Amplification of cyclic AMP generation reveals agonistic effects of certain β-adrenergic antagonists. Mol Pharmacol 37:44-49.
25. Kaumann AJ, Engelhardt S, Hein L, Molenaar P, and Lohse M (2001) Abolition of (-)-CGP 12177-evoked cardiostimulation in double beta1/beta2-adrenoceptor knockout mice. Obligatory role of beta1-adrenoceptors for putative beta4-adrenoceptor pharmacology. Naunyn Schmiedeberg's Arch Pharmacol 363:87-93.
26. Kenakin TP (1995) Agonist-receptor efficacy: agonist trafficking of receptor signals. Trends Pharmacol Sci 16:232-238.
27. 13 results in shape change and Rho/Rho-kinase-mediated myosin light chain phosphorylation in mouse platelets. J Cell Biol 144:745-754.
28. Kobilka B (1992) Adrenergic receptors as models for G protein-coupled receptors. Annu Rev Neurosci 15:87-114.
29. 1-adrenergic receptors. J Pharmacol Exp Ther 294:923-932.
30. Lefkowitz RJ, Pierce KL, and Luttrell LM (2002) Dancing with different partners: protein kinase A phosphorylation of seven membrane-spanning receptors regulates their G-protein coupling specificity. Mol Pharmacol 62:971-974.
31. 2-adrenergic receptor-Src protein kinase complexes. Science (Wash DC) 283:655-661.
32. Marano G, Palazzesi S, Fadda A, Vergari A, and Ferrari AU (2002) Attenuation of aortic banding-induced cardiac hypertrophy by propranolol is independent of beta-adrenoceptor blockade. J Hypertens 20:763-769.
33. 1-receptor to the nucleus. Mol Pharmacol 59:1012-1021.
34. MERIT-HF (1999) Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353:2001-2007.
35. Morgan TO, Anderson AIE, and MacInnis RJ (2001) ACE inhibitors, beta-blockers, calcium blockers and diuretics for the control of systolic hypertension. Am J Hypertens 14:241-247.
36. Nicholas G, Oakley C, Pouleur H, Rousseau MF, Ryden LE, and Wellens H (1990) Xamoterol in severe heart failure. The Xamoterol in Severe Heart Failure Study Group. Lancet 336:1-6.
37. Penn RB, Parent JL, Pronin AN, Panettieri RA, and Benovic JL (1999) Pharmacological inhibition of protein kinases in intact cells: antagonism of β adrenergic receptor ligand binding by H-89 reveals limitations of usefulness. J Pharmacol Exp Ther 288:428-437.
38. Port JD and Bristow MR (2001) Altered beta-adrenergic receptor gene regulation and signaling in chronic heart failure. J Mol Cell Cardiol 33:887-905.
39. 2-adrenergic receptor activates extracellular signal-regulated kinases (ERKs) via the small G-protein Rap1 and the serine/threonine kinase B-Raf. J Biol Chem 275:25342-25350.
40. Seta K, Nanamori M, Modrall JG, Neubig RR, and Sadoshima (2002) AT1 receptor mutant lacking heterotrimeric G protien coupling activates the Src-Ras-ERK pathway without nuclear translocation of ERKs. J Biol Chem 277:9268-9277.